A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity
Authors:
Open Access
- 24 November 2020
- journal article
- review article
- Published by Wiley in HemaSphere
- Vol. 4 (6)
Abstract
The knowledge of cancer origin and the subsequent tracking of disease evolution represent unmet needs that will soon be within clinical reach. This will provide the opportunity to improve patient's stratification and to personalize treatments based on cancer biology along its life history. In this review, we focus on the molecular pathogenesis of multiple myeloma (MM), a hematologic malignancy with a well‐known multi‐stage disease course, where such approach can sooner translate into a clinical benefit. We describe novel insights into modes and timing of disease initiation. We dissect the biology of the preclinical and pre‐malignant phases, elucidating how knowledge of the genomics of the disease and the composition of the microenvironment allow stratification of patients based on risk of disease progression. Then, we explore cell‐intrinsic and cell‐extrinsic drivers of MM evolution to symptomatic disease. Finally, we discuss how this may relate to the development of refractory disease after treatment. By integrating an evolutionary view of myeloma biology with the recent acquisitions on its clonal heterogeneity, we envision a way to drive the clinical management of the disease based on its detailed biological features more than surrogates of disease burden.Keywords
This publication has 153 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white womenBlood, 2010
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studyBlood, 2009
- The cancer genomeNature, 2009
- Multiple Myeloma Cancer Stem CellsJournal of Clinical Oncology, 2008
- Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple MyelomaNew England Journal of Medicine, 2007
- The molecular classification of multiple myelomaBlood, 2006
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantationBlood, 2006